Literature DB >> 33548303

Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial.

Jerry Tsai1, Anna L Chien1, Noori Kim1, Saleh Rachidi1, Brian M Connolly1, Hester Lim1, Sabrina Sisto Alessi César1, Sewon Kang1, Luis A Garza2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33548303      PMCID： PMC8329126          DOI： 10.1016/j.jaad.2021.01.098

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   15.487


× No keyword cloud information.
  5 in total

1.  Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma.

Authors:  S A Gandolfi
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-02       Impact factor: 4.799

2.  Brimonidine effective but may lead to significant rebound erythema.

Authors:  Dan Ilkovitch; Rebecca G Pomerantz
Journal:  J Am Acad Dermatol       Date:  2014-05       Impact factor: 11.527

Review 3.  Difference in vasoconstrictors: oxymetazoline vs. brimonidine.

Authors:  Nwanneka Okwundu; Abigail Cline; Steven R Feldman
Journal:  J Dermatolog Treat       Date:  2019-08-12       Impact factor: 3.359

4.  Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.

Authors:  J Fowler; M Jarratt; A Moore; K Meadows; A Pollack; M Steinhoff; Y Liu; M Leoni
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

Review 5.  Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents.

Authors:  W P Boger
Journal:  Surv Ophthalmol       Date:  1983-12       Impact factor: 6.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.